Page Banner
Mayo Clinic Laboratories > Oncology > MayoComplete

MAYOCOMPLETE

View now Hematology, oncology, and hereditary test selection guide
Answers from the Lab Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection
Video Learn more about the future of comprehensive cancer care

Comprehensive cancer care starts with MayoComplete

Understanding the unique genetic features of patients' tumors is essential to helping physicians select from an array of treatment options to devise an optimal care plan. Comprehensive genetic testing is the first step in starting cancer patients down the right path.

Our full menu of MayoComplete solid tumor testing includes a comprehensive, 515-gene panel and multiple disease-specific panels, which span the cancer spectrum. Our testing uses next-generation sequencing (NGS) and has been validated for the use of cytology specimens, ensuring more patients receive personalized answers to guide their care.

MAYOCOMPLETE Test menu

Pan cancer Pan cancer
Pan cancer

Our 515-gene panel analyzes mutations, rearrangements, and/or amplifications as well as evaluates tumor mutation burden status and microsatellite instability.

Colorectal cancer Colorectal cancer
Colorectal cancer

Our next-generation sequencing colorectal cancer panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.

Gastrointestinal stromal tumors Gastrointestinal stromal tumors
Gastrointestinal stromal tumors

Our MayoComplete noncolorectal gastrointestinal cancer evaluation assists in diagnosis by evaluating for mutations in the PDGFRA and KIT genes.

Gynecological cancer Gynecological cancer
Gynecological cancer

We offer three MayoComplete gynecological cancer panels, including comprehensive and focused panels, that evaluate for genetic variations associated with diagnosis, prognosis, and treatment response.

Liquid biopsy Liquid biopsy
Liquid biopsy

Our liquid biopsy panel is a cell-free DNA test that uses next-generation sequencing to evaluate peripheral blood for 33 genes. The assay detects single nucleotide variants, insertions, and deletions, as well as translocations and microsatellite instability (MSI).

Lung cancer Lung cancer
Lung Cancer

Our targeted lung cancer panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.

Melanoma Melanoma
Melanoma

Our melanoma panel identifies variants in 17 genes associated with diagnosis, prognosis, and treatment guidance. Offering increased sensitivity for heightened accuracy, our melanoma evaluation includes full exonic sequencing of the genes, as opposed to evaluating only targeted areas.

Neuro-oncology Neuro-oncology
Neuro-oncology

Our next-generation sequencing neuro-oncology panel evaluates for mutations and rearrangements in 160 genes, including most abnormalities described by the World Health Organization 2021 classifications.

Sarcoma Sarcoma
Sarcoma

Our comprehensive sarcoma fusion panel includes 169 genes and assesses mutations and fusions described in more than 50 types of soft tissue, bone, and other mesenchymal tumors. The panel is designed to provide the most comprehensive analysis by including 124 gene fusion pairs, 274 fusion variants, and novel gene partner detection.

Urologic cancer Urologic cancer
Urologic cancer

Our three focused MayoComplete next-generation sequencing urology panels were carefully curated by a collaborative team of clinical experts, geneticists, and genetic counselors to include only clinically relevant genes. They include testing for kidney cancer, bladder and prostate cancer, and fibromyomatous RCC.

MayoComplete next-generation sequencing overview MayoComplete next-generation sequencing overview
MayoComplete next-generation sequencing overview

Designed using our extensive clinical experience and informed by the latest in cancer biomarker discovery and treatments, our suite of MayoComplete next-generation sequencing panels puts patients on the right path.

News and updates

The latest

Whole transcriptome RNA sequencing featured image
Whole transcriptome RNA sequencing

Learn more about how Mayo Clinic Laboratories approach to whole transcriptome RNA sequencing provides the most comprehensive detection of gene fusions in solid tumors through use of next-generation sequencing to identify fusions in 1,445 genes.

Learn more
Comprehensive panel boosts GIST diagnosis sensitivity

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Melanoma panel provides more tumor information

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Colorectal panel provides detailed cancer information

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Focused lung panel informs the use of targeted cancer therapies

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

Patient-focused pragmatism: The Mayo Clinic innovation model

In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.

A “sandbox” for innovation: The Advanced Diagnostics Laboratory

Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.

MayoComplete Solid Tumor Panel

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

Resources
View now Hematology, oncology, and hereditary test selection guide
View MayoComplete solid tumor testing negative report example
View MayoComplete solid tumor testing positive report example
Download Tissue requirements for solid tumor NGS
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.

(BETA) Choose a language to view this content in:
About the translation.